Back to all peptides

    Complete this with

    The GLP-1 Protocol

    Evidence before a stack. Approval, benefit and risk depend on the specific compound and indication. Nervous-system coaching does not replace clinical assessment. Explore the 7-Day Reset and your matched The GLP-1 Protocol for optional wellbeing support, not permission to self-prescribe.

    Anchor 09 · Metabolic Peptide ProtocolClinically established

    Semaglutide & Tirzepatide

    GLP-1 / GIP receptor agonists

    Lower the noise. Improve the signal.

    These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.

    42 currently viewing

    Evidence classification

    Clinically established. FDA-approved or equivalent regulatory authorization for at least one indication.

    Evidence reviewed · 2026-10-21

    What the evidence actually supports

    Semaglutide & Tirzepatide

    These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.

    Protect nutrition, strength and hydration with an individual plan. An Anchor, supplement bundle or fixed fasting window is not a medical prerequisite. Obesity treatment may be long term; stopping commonly leads to regain, and a taper is not proven to prevent it. Do not change prescribed treatment based on wearable readiness alone.

    New formulations and the metabolic pipeline

    Oral Wegovy received US FDA approval on 22 December 2025. In OASIS 4 (307 adults without diabetes), mean body-weight change at 64 weeks was −13.6% versus −2.2% with placebo in the treatment-policy analysis. This is an oral formulation, not proof that every semaglutide product is interchangeable. Wegovy injection also gained a US accelerated MASH indication in August 2025 for noncirrhotic disease with F2–F3 fibrosis; that is not a liver-detox or longevity claim.

    CagriSema has published phase 3 evidence: REDEFINE 1 reported −20.4% versus −3.0% at 68 weeks in the treatment-policy analysis. Retatrutide's published phase 2 trial reported −24.2% versus −2.1% at 48 weeks, a secondary time point. These are separate trials, not a head-to-head ranking. No approval was verified here for either pipeline agent; trial success and commercial release are different events. Current Portuguese supply and reimbursement remain unverified.

    Semaglutide: the eye-safety update

    On 6 June 2025, EMA concluded that NAION, an optic-nerve condition, is a very rare adverse effect of semaglutide. Observational estimates in adults with type 2 diabetes corresponded to about one additional case per 10,000 person-years; that estimate is not a risk calculation for every individual.

    Sudden vision loss or rapidly worsening eyesight requires urgent medical assessment. This warning is specific to semaglutide, not established as an identical risk for all peptides or incretin medicines. The clinician handles treatment decisions.

    Before you layer this peptide

    Foundation checklist

    These are discussion points, not eligibility rules. No wearable score, supplement stack or thirty-day routine establishes that Semaglutide & Tirzepatide is appropriate.

    • Completed the 7-Day Reset — optional support for observing sleep, stress and recovery.
    • Review sleep and recovery. A diary can help; a wearable is optional and cannot diagnose a nervous-system state.
    • Investigate persistent symptoms. Fatigue, pain or cognitive changes may have medical causes. HRV alone cannot identify them.
    • Running the 5 pillars of The GLP-1 Protocol — supplement stack, timing dashboard, device pairings, and macro rules. The full protocol is available inside the Anchor.
    • Nutrition matched to your health and treatment. Fasting and supplements are not universal requirements; review them with your clinician.
    • Clinical review when indicated. Your clinician decides which tests, if any, are appropriate; a blanket panel is not a safety certificate.
    • Qualified prescriber on board. Semaglutide & Tirzepatide is sourced, dosed, and monitored under medical supervision — not from a research-chemical vendor.
    Open the The GLP-1 Protocol

    Mechanism of action

    These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.

    Who this is for

    • ●Readers comparing actual human evidence with marketing claims.
    • ●Adults discussing an appropriate, locally authorized treatment or clinical trial with their clinician.

    Who this is not for

    • ○Self-prescribing, sourcing research vials or substituting this guide for clinical assessment.
    • ○Pregnancy, breastfeeding or complex medical conditions without individualized medical review.

    Treatment and protocol boundaries

    No self-injection or experimental dosing instructions. Approved medicines follow their own label and prescriber plan.

    Clinical boundaryProtect nutrition, strength and hydration with an individual plan. An Anchor, supplement bundle or fixed fasting window is not a medical prerequisite. Obesity treatment may be long term; stopping commonly leads to regain, and a taper is not proven to prevent it. Do not change prescribed treatment based on wearable readiness alone.

    Sourcing & quality

    Where this comes from matters more than the molecule

    Use only lawfully supplied medicines for an appropriate indication, or a formally approved clinical trial. A research-use label or purity assay does not make a product suitable for human treatment. Ask a clinician or pharmacist to verify local authorization and availability; US approval alone does not establish access in Portugal.

    Support around treatment

    Sleep, food, movement and symptom tracking are support pillars, not proven peptide enhancers. Supplements and devices can have their own risks; more is not automatically better.

    Sleep and recovery

    Track how you feel and function; sleep is support, not evidence that a peptide works.

    Nutrition and movement

    Individualize food and activity with your care team. Supplement combinations are not automatically necessary or safe.

    Journal and clinician review

    Record symptoms and treatment changes without assuming every change was caused by the molecule.

    Known risks & side effects

    • ▲Gastrointestinal effects, dehydration and inadequate intake need review, especially during dose escalation.
    • ▲Persistent severe abdominal pain, repeated vomiting or inability to keep fluids down require prompt medical assessment.
    • ▲Gallbladder disease, pancreatitis warnings and product-specific contraindications must be reviewed using the current label.
    • ▲Lean mass can fall during weight loss; the proportion varies and is not the same as measured muscle loss.
    • ▲Weight regain after stopping is common. Long-term treatment can be appropriate; there is no universal graduation deadline.

    Common questions

    What does the current evidence support?

    These medicines have substantial human evidence for defined metabolic indications. Approval belongs to a product, indication and country—not to every vial bearing the molecule's name. Appetite effects are not proof of nervous-system regulation or dorsal-vagal shutdown.

    Does an Anchor replace clinical care?

    No. An Anchor offers optional coaching support. It is not a prescribing service, a safety certificate or a medical requirement before an approved treatment.

    Where are the dosing instructions?

    Protect nutrition, strength and hydration with an individual plan. An Anchor, supplement bundle or fixed fasting window is not a medical prerequisite. Obesity treatment may be long term; stopping commonly leads to regain, and a taper is not proven to prevent it. Do not change prescribed treatment based on wearable readiness alone.

    The matched Anchor

    Complete this peptide with The GLP-1 Protocol

    Optional coaching for the everyday habits around care. This Anchor does not establish peptide efficacy, authorize prescribing or replace medical treatment.

    "Stop losing muscle. Start burning fat. Protect the engine."

    Targets

    Nutrition, Strength & Treatment Tolerance

    Category

    Metabolic

    Fasting window

    12:12 max

    Inside the full Anchor

    • ·5 supplement pillars with sourced products
    • ·Hour-by-hour timing dashboard
    • ·Device pairings & macro rules
    • ·Current protocol in-app — lifetime access
    Unlock the full The GLP-1 Protocol

    Build the floor first

    Interventions without an Anchor is biohacking. With one, it's architecture.

    The Metabolic Peptide Protocol sets the supplement, device, and fasting baseline this peptide is designed to layer on top of.

    See the Metabolic Peptide Protocol Discover what fits you

    Medical disclaimer. Kokorology is an educational publication. The information on this page is not medical advice and does not establish a doctor-patient relationship. Peptides are pharmacologically active compounds. Several peptides referenced across this site are not approved by the FDA, EMA, or equivalent regulators for general wellness use; some are research compounds or approved only for narrow indications (e.g. tesamorelin for HIV-associated lipodystrophy). The FDA has issued warnings about unapproved compounded GLP-1 products. Never start, change, or stop a peptide protocol without a qualified prescriber. If you are pregnant, nursing, taking prescription medication, or have a chronic condition, do not begin any protocol described here without medical supervision.